CSRC approves Weigao Hematology's IPO registration on the Shanghai Stock Exchange

On March 21, the China Securities Regulatory Commission issued the "Approval for the Initial Public Offering of Shares by Shandong Weigho Blood Purification Products Co., Ltd." It is reported that Weigho Blood Purification intends to be listed on the main board of the Shanghai Stock Exchange, with Huatai United Securities as the sponsor, intending to raise 1.351 billion yuan. According to the prospectus, in order to better meet the treatment needs of patients with end-stage renal disease (ESRD) at all stages, Weigho Blood Purification focuses on two main tracks of blood dialysis and peritoneal dialysis, supplemented by the sale of dialysis accessories, making it one of the domestic manufacturers with the most comprehensive product lines of blood purification medical products. The company's blood dialysis products mainly include blood dialyzers, blood dialysis tubing, and blood dialysis machines, while peritoneal dialysis products mainly include peritoneal dialysis fluid. Since its establishment, Weigho Blood Purification has always focused on the research and development, production, and sales of blood purification medical products, with its main products revolving around blood dialysis and peritoneal dialysis areas, supplemented by the sale of dialysis accessories. It is one of the domestic manufacturers with the most comprehensive product lines of blood purification medical products. The actual funds raised in this issuance, after deducting issuance expenses, are planned to be used for the following projects: